Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000940881 | SCV001086750 | likely benign | not provided | 2023-07-10 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002505396 | SCV002799888 | likely benign | Distichiasis-lymphedema syndrome | 2021-09-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003338875 | SCV004067949 | uncertain significance | Inborn genetic diseases | 2023-09-12 | criteria provided, single submitter | clinical testing | The c.605A>C (p.D202A) alteration is located in exon 1 (coding exon 1) of the FOXC2 gene. This alteration results from a A to C substitution at nucleotide position 605, causing the aspartic acid (D) at amino acid position 202 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |